Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset FTLF
Coverage 240,410 Raw stories ingested 36,560 rewritten in CS_CZ • 0 to rewrite (last 7 days).
Agents 7 Live Pipeline agents
  • FMP Stock News Fetch every minute running now
  • FMP Forex News Fetch every 5 min 1m ago
  • CoinGecko News Fetch every 5 min 1m ago
  • FIO Stock News Fetch every 10 min 3m ago
  • Patria Stock News Fetch every 10 min 3m ago
  • Editorial rewrite Rewrite every minute 1m ago
  • Asset sync Assets every 1 hour 1h ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

View
Language
Relevance
Clear
Details Date Content Source Relevance
2026-10-25 05:14 20h ago
2026-10-24 23:02 1d ago
Tržby FitLife Brands zůstaly stabilní navzdory slabší poptávce
FTLF FitLife Brands
FMP Stock News 92
Original source text
FitLife Brands NASDAQ: FTLF outlined its strategy to grow a portfolio of nutritional supplement and wellness brands through acquisitions, e-commerce sales and operational improvements, while acknowledging recent organic-growth headwinds tied to Amazon changes, specialty retail traffic and weakening demand in certain product categories.

Chairman and Chief Executive Officer Dayton Judd said FitLife owns 16 brands and operates as an asset-light business, owning brand intellectual property while using third parties for manufacturing. The company sells products through e-commerce and wholesale channels, including GNC franchise stores, Walmart, CVS, Walgreens, Costco Canada, Sprouts, Fresh Thyme and Whole Foods.

Get FitLife Brands alerts:

About half of FitLife's revenue comes from online sales, Judd said. The company does not sell products directly to Amazon, but instead operates as the seller of its brands on the marketplace and manages its own product pages and advertising.

Growth Strategy Built on Acquisitions
Judd described FitLife's transformation since he became interim CEO in 2018, when the company was facing debt default and was “literally on the verge of bankruptcy.” He said the company had been heavily dependent on GNC, with about 99% of revenue coming from wholesale sales before FitLife expanded its online operations, particularly on Amazon.

FitLife subsequently used cash flow from its existing businesses to acquire additional brands, seeking both growth and a more diversified customer base. Its recent transactions included Nutrology in April 2021, Mimi's Rock Corp., which included the Dr. Tobias brand, in February 2023, MusclePharm assets out of bankruptcy in October 2023, and Irwin Naturals more than a year ago.

Judd said the Irwin Naturals purchase roughly doubled FitLife's size. On a last-12-month basis, he said FitLife had more than $100 million in revenue and adjusted EBITDA of more than $14 million.

The company uses debt for acquisitions and seeks to pay it down afterward rather than issuing stock, according to Judd. He said FitLife has not issued shares for acquisitions and has a simple common-stock capital structure. Judd also said he owns about 60% of the company on a fully diluted basis, which he characterized as aligning management with shareholders.

Margin Improvement Efforts
President Ryan Hansen said the Irwin Naturals acquisition lowered FitLife's blended gross-margin profile because Irwin historically operated with somewhat lower margins. He said the combined company is currently generating gross margins in the mid-30% to high-30% range, compared with low-40% margins before the acquisition.

Management is working to improve those margins by extending shelf life across Irwin products where possible. Hansen said most Irwin products historically had two-year shelf lives, while retailers often require products to have at least 12 months of dating remaining before putting them on shelves.

That requirement effectively left the company with about a year to sell products after manufacturing, he said. Irwin had been recording more than $1 million and potentially close to $2 million annually in inventory obsolescence. FitLife has worked to transition formulas it owns to three-year shelf lives, which would double the sellable period from 12 months to 24 months.

Hansen said the benefit will take time to materialize because the company must first cycle through older inventory. FitLife also has made changes to its third-party logistics, transportation and distribution arrangements that are expected to reduce fulfillment costs. In addition, management has made SG&A and headcount adjustments following the Irwin acquisition.

Organic Challenges and Portfolio Response
Hansen said FitLife operates in a fragmented supplement market with favorable long-term category trends, but said growth has not been evenly distributed among competitors. The company identified three recent challenges to organic sales:

Amazon algorithm changes that have favored brands with traffic and presence outside the Amazon ecosystem.
Lower foot traffic at specialty retailers, where consumers may be more sensitive to premium prices.
Exposure to declining segments, including weight-loss and cleanse products affected by GLP-1 drugs, as well as certain men's health and testosterone-focused products.

Hansen said FitLife is responding by building external traffic through TikTok, Google and Meta advertising, while also pursuing generative-engine optimization to improve discovery through artificial-intelligence search tools. He said Irwin, which was already broadly distributed outside Amazon, has performed above the company's expectations since its acquisition.

Management also plans to introduce products outside the categories facing pressure. Hansen said the company's product-development pipeline is focused on areas where FitLife believes it has “permission to win” or an existing presence that can be expanded.

Judd emphasized that the company is not experiencing a rapid revenue decline. He said quarterly revenue over the prior three quarters had generally been in the $25 million to $26 million range, with declining brands and channels being substantially or fully offset by growth elsewhere. Still, he said FitLife needs to restore organic growth to support a higher valuation multiple.

Acquisition Market Remains Difficult
While FitLife intends to remain a consolidator in the supplement industry, Judd said the company has not found a transaction it feels compelled to pursue recently. He said FitLife has signed more than 75 nondisclosure agreements, and possibly close to 100, over roughly five years but has completed four deals.

Over the past year, Judd said the company reviewed about two dozen potential transactions and did not see a single business presented as growing. Many potential targets were direct-to-consumer businesses experiencing declines while spending heavily on advertising in an effort to stabilize sales, he said.

About FitLife Brands (NASDAQ:FTLF)FitLife Brands, Inc is a developer, manufacturer and marketer of nutritional supplements. The company focuses on products intended to support sports performance, weight management, energy, recovery and general health, serving consumers through a portfolio of branded dietary supplements.

FitLife's product portfolio has included brands such as NDS Nutrition, PMD Sports, iSatori and Muscle Elements. Its offerings include powders, capsules, tablets and other supplement formats marketed to athletes, fitness enthusiasts and consumers seeking wellness and nutrition products.

The company sells its products through e-commerce channels, specialty retailers, gyms and other distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in FitLife Brands Right Now?Before you consider FitLife Brands, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FitLife Brands wasn't on the list.

While FitLife Brands currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
2026-08-13 13:56 2mo ago
2026-08-13 09:40 2mo ago
FitLife Brands překonala odhady zisku i tržeb
FTLF FitLife Brands
FMP Stock News 78
Original source text
FitLife Brands Inc. (FTLF - Free Report) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +11.11%. A quarter ago, it was expected that this company would post earnings of $0.14 per share when it actually produced earnings of $0.17, delivering a surprise of +21.43%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

FitLife Brands , which belongs to the Zacks Medical - Products industry, posted revenues of $26.55 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.19%. This compares to year-ago revenues of $16.13 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

FitLife Brands shares have lost about 36.9% since the beginning of the year versus the S&P 500's gain of 13.2%.

What's Next for FitLife Brands ?While FitLife Brands has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for FitLife Brands was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.27 on $29.75 million in revenues for the coming quarter and $0.83 on $109.02 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Medtronic (MDT - Free Report) , is yet to report results for the quarter ended July 2026. The results are expected to be released on September 1.

This medical device company is expected to post quarterly earnings of $1.39 per share in its upcoming report, which represents a year-over-year change of +10.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Medtronic's revenues are expected to be $9.48 billion, up 10.5% from the year-ago quarter.